Russian Application of Sputnik V Vaccine for WHO Vaccine Prequalification Among the First Applications Submitted
Moscow, October 27, 2020 – The Russian Direct Investment Fund, (RDIF, Russia ' s sovereign wealth fund), has submitted applications to the World Health Organization (WHO) for accelerated registration (Emergency Use Listing, EUL) and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 27, 2020 Category: Pharmaceuticals Source Type: clinical trials
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences.Intervention and ComparatorCOVID- 19 confirmed patients (using the RT-PCR test or CT scan) will be randomly assigned to one of two groups. The intervention group (Arms1) will be treated with lopinavir / ritonavir (Kaletra) + high dose Interferon- β 1a (Recigen) and the control group will be treated with lopinavir / ritonavir (Kaletra) + low dose Interferon-β 1a (Recigen) (the base therapeutic regimen). Both groups will receive standard care consisting of the necessary oxygen support, non-invasive, or invasive mecha...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials
Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial
AbstractObjectivesGeneral: To assess the safety, efficacy and dose response of convalescent plasma (CP) transfusion in severe COVID-19 patientsSpecific:a. To identify the appropriate effective dose of CP therapy in severe patientsb. To identify the efficacy of the therapy with their end point based on clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortalityc. To assess the clinical improvement after CP transfusion in severe COVID-19 patientsd. To assess the laboratory improvement after CP transfusion in severe COVID-19 patientsTrial DesignThis is a multicentre, mul...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials
Gilead Sciences Statement on the Solidarity Trial
October 15, 2020 -- We are aware that initial data from the World Health Organization’s (WHO) SOLIDARITY Trial has been made public prior to publication in a peer-reviewed journal. The emerging data appear inconsistent with more robust... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 15, 2020 Category: Pharmaceuticals Source Type: clinical trials
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesTo evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19.To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (6...
Source: Trials - October 15, 2020 Category: Research Source Type: clinical trials
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Conditions: SARS-CoV-2 Infection; COVID-19; Moderate and Severe COVID-19 Interventions: Other: Standard of Care (SoC); Drug: Remdesivir Sponsors: Professor Dr. Bernd Mühlbauer; Dept. of Statistics and Medical Biometry, University of Bremen; INSERM (Institut national de la santé et de la recherche médicale), Paris, France; World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2020 Category: Research Source Type: clinical trials
